Fmr LLC Inozyme Pharma, Inc. Transaction History

Fmr LLC

$1.52 Trillion
Q2 2024

A detailed history of Fmr LLC transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Fmr LLC holds 2,477,427 shares of INZY stock, worth $9.96 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,477,427

Previous 1,967,432 25.92%

Holding current value

$9.96 Million

Previous $15.1 Million 26.68%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.33 - $7.31 $2.21 Million - $3.73 Million	509,995 Added 25.92%	2,477,427 $11 Million
Q1 2024 May 13, 2024	SELL	$4.14 - $7.66 $1.26 Million - $2.34 Million	-304,874 Reduced 13.42%	1,967,432 $15.1 Million
Q4 2023 Feb 13, 2024	SELL	$2.71 - $4.5 $522,829 - $868,167	-192,926 Reduced 7.83%	2,272,306 $9.68 Million
Q3 2023 Nov 13, 2023	BUY	$4.09 - $7.0 $7.02 Million - $12 Million	1,716,398 Added 229.21%	2,465,232 $10.4 Million
Q2 2023 Aug 11, 2023	BUY	$4.93 - $6.74 $225,981 - $308,948	45,838 Added 6.52%	748,834 $4.17 Million
Q1 2023 May 11, 2023	BUY	$1.3 - $5.73 $913,894 - $4.03 Million	702,996 New	702,996 $4.03 Million
Q3 2022 Nov 10, 2022	SELL	$2.57 - $5.45 $1,128 - $2,392	-439 Reduced 0.07%	609,380 $1.63 Million
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.96 $720 - $1,341	225 Added 0.04%	609,819 $2.91 Million
Q1 2022 May 13, 2022	BUY	$3.87 - $7.55 $828 - $1,615	214 Added 0.04%	609,594 $2.49 Million
Q2 2021 Aug 13, 2021	BUY	$15.19 - $21.2 $9.26 Million - $12.9 Million	609,380 New	609,380 $10.4 Million

Others Institutions Holding INZY

# of Institutions

Shares Held

52.5M

Call Options Held

17.6K

Put Options Held

2.7K

View Full List

About Inozyme Pharma, Inc.

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $161M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

More about INZY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account